Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NICE Rejects Javlor, But Could Products For Unmet Clinical Needs Be Rethought?

This article was originally published in The Pink Sheet Daily

Executive Summary

U.K. cost watchdog rejects Pierre Fabre's Javlor even though it extended the survival of patients with metastatic bladder cancer.
Advertisement

Related Content

NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
NICE Continues Tough Approach On Cancer Drugs, Rejects Tarceva, Javlor and Yondelis
UK's New Cancer Drug Fund Might Not Alleviate Regional Access Disparities
Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer
Roche To Appeal NICE's Rejection Of Herceptin For HER2-positive Stomach Cancer

Topics

Advertisement
UsernamePublicRestriction

Register

PS071505

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel